IL1B and non-small cell lung carcinoma: Although, many large questions remain, there is no doubt that human clinical studies and the recent success of the CANTOS trial using an IL-1β inhibitory antibody will pave the way to the investigation of novel approaches to targeting not only traditional checkpoint blockade therapies but also immune checkpoint therapies to fight the residual burden of unmet need of NSCLC patients.